Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.13% 1,518.50 1,523.00 1,524.00 1,539.00 1,511.50 1,521.00 1,725,893 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,335.3 179.9 37.5 42.0 13,297

Smith & Nephew Share Discussion Threads

Showing 676 to 698 of 975 messages
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
Smith & Nephew has been raised to 'buy' from 'neutral' at Goldman Sachs on Monday due to improving fundamentals and under-appreciated strategic value. Goldman also increased its target price on the stock, up to 1300p from 1200p. The bank said Smith & Nephew's stock has been a notable under-performer despite solid FY14 results, with sentiment driven largely by questions on whether the company is still a likely acquisition target. "We continue to believe that further consolidation in orthopaedics - with Smith & Nephew being acquired by a larger player - makes strategic sense, though recognise the multiple hurdles to a potential transaction," said Goldman. The bank expects 2015 to mark an important turning point for the company. "We expect organic top-line growth to re-accelerate to around 5% per year versus the 2009-14 average of below 3% as Smith & Nephew benefits from ongoing utilisation recovery in the US, and addresses some of the recent causes of underperformance in the wound business," said Goldman. It added that it also sees meaningful opportunities for margin expansion "driven by integration of Arthrocare and the $120m efficiency program announced in 2014."
Also bought in on recent fall. Only a matter of time before they are bought out at a decent premium. Quality operation.
its the oxman
Interesting to see Matt Earl (The Dark Destroyer)as gone long on the stock here. hes the chap who alerted everyone to his TUNG short and as a fantastic record. Taken from his Blog. Heres what he says........ .Wednesday, 4 March 2015 Smith & Nephew (SN/) ... coldwater morning I've bought a wodge of Smith & Nephew (SN/ LN) at 1140p/shr and an 1100 put. Yesterday's move by Stryker (SYK US), in announcing a $2 billion extension to its authorised buy back scheme, seems to me to be a mere attempt to pour cold water over S&N's potential purchase price. And so I reckon that suggests a bid could be imminent. North of 1350p/shr would be satisfactory. No doubt we will hear more from Matt.
Smith & Nephew plc Stock Rating Reaffirmed by Sanford C. Bernstein (SN) March 3rd, 2015 Updated 5th March 2015 Smith & Nephew plc (LON:SN)‘s stock had its “outperform221; rating restated by investment analysts at Sanford C. Bernstein in a note issued to investors on Tuesday. They currently have a GBX 1,350 ($20.80) target price on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 12.68% from the company’s current price. Shares of Smith & Nephew plc (LON:SN) traded down 5.34% during mid-day trading on Tuesday, hitting GBX 1135.00. The stock had a trading volume of 11,677,271 shares. Smith & Nephew plc has a one year low of GBX 858.50 and a one year high of GBX 1211.00. The stock’s 50-day moving average is GBX 1180. and its 200-day moving average is GBX 1093.. The company’s market cap is £10.136 billion. Several other analysts have also recently commented on the stock. Analysts at Numis Securities Ltd reiterated a “hold” rating and set a GBX 1,105 ($17.03) price target on shares of Smith & Nephew plc in a research note on Monday. Analysts at AlphaValue reiterated a “buy” rating and set a GBX 1,399 ($21.56) price target on shares of Smith & Nephew plc in a research note on Friday. Analysts at Cenkos Securities Ltd reiterated a “buy” rating and set a GBX 1,200 ($18.49) price target on shares of Smith & Nephew plc in a research note on Thursday, February 12th. Finally, analysts at Berenberg Bank raised their price target on shares of Smith & Nephew plc from GBX 990 ($15.26) to GBX 1,080 ($16.64) and gave the company a “hold” rating in a research note on Monday, February 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of GBX 1,107.59 ($17.07). Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management.
Healthpoint = Endpoint. HP802 is dead in the water.
That's why I bought 'em.
Questor share tips for 2015 Takeover Target Smith & Nephew £11.88 Buy Smith & Nephew has been one of those FTSE names which has spent the best part of five years as a hotly-tipped takeover target. But 2015 could be the year that it all comes true for shareholders in the UK’s biggest orthopaedics company. A six-month cool off period which prevented US rival Stryker from making a return for the British artificial hip maker expired in November. Takeover rumours sent shares 6pc higher on Christmas Eve and the smart money is now on a deal being struck in the first half of the year. A bid valuing the group at £13bn would equal about £14.55 a share a 28pc premium to the year end closing price. Stryker has a huge impetus to act now to avoid being sidelined by the wave of consolidation that has already taken place in the sector: Johnson & Johnson has already acquired Swiss med tech rival Synthes, Zimmer has snapped up Biomet and Medtronic and Covidien are in the process of pushing through their $43bn deal through competition regulators. Either way, Smith & Nephew is benefiting from an ageing population and a boom in technology which has transformed sports medicine. In October, it reported a nine-month trading profit up 1pc to £695m on sales 2pc higher at £3.2bn. The shares trade on 20 times forecast earnings, and offer a prospective dividend yield of 1.7pc. Always the bridesmaid, this could be the year Smith & Nephew makes it to the altar. Buy.
is there a link to that piece ?...ta
A six-month cool off period which prevented US rival Stryker from making a return for the British artificial hip maker expired in November. Takeover rumours sent shares 6pc higher on Christmas Eve and the smart money is now on a deal being struck in the first half of the year. A bid valuing the group at £13bn would equal about £14.55 a share a 28pc premium to the year end closing price.
chatter says £13 per share or £13.25
ADS closed at $38 which on the basis of 2:1 ord, at $1-55,equates to a London equivalent of £12-26p some 12.5% higher than Tuesday's close.
Up 13% in the states on Stryker comments.
bill hunt
Director buying
Sp in the hands of rumour mongers for now. Volatility rules Ok.
Smith & Nephew's shares rose after chief executive Olivier Bohuon reportedly told employees he has no intention of leaving the company following speculation that he was taking the helm of Sanofi. Bohuon told employees at a town hall meeting in Switzerland that he was "very happy" at the company, according to Bloomberg. Earlier this week French newspaper Le Figaro reported that Sanofi chairman Serge Weinberg had chosen Bohuon as successor to Chris Viehbacher, who stepped down as chief executive in October
bw Sold half of mine today at £11.41. Hedging my bets - it may be better to travel than to arrive. I am not sure that the Americans wll bid. The half that is left are now at an average of £2.10 each, so will give me a good income yield going forward. Your purchase could be well timed. Fingers, and toes, crossed. red
Red - Bought these a while back in the hope/expectation another bid would come at the end of the six month period - which is today. We live in hope.
Fact or fiction?
US outfit Stryker is laying the groundwork of another bid for British rival Smith&Nephew. The manufacturer of surgical implants has been in discussion with advisers regarding the possible financing of a deal and the potential anti-trust hurdles which it might face, should it proceed with a transaction which is valued at approximately $16bn. The potential takeover target and its advisers were already aware of the American company's interest, but it was still possible that its suitor might pull out, Bloomberg reported. Stryker was considering pursuing a so-called tax-inversion structure, which would see it re-domicile to the UK. The legal limitation on the US, Michigan-based company's ability to make another take-over attempt, after it pulled out from a bid earlier in the year, was set to expire in the week just started. As of 14:54 shares of Smith&Nephew were rising by 4.33% to 1,137.15p.
Medical devices maker Smith & Nephew posted a 3% increase in both revenue and profit for the third quarter, thanks to an improvement in its emerging and international markets units, recent product launches and investment in the sales force. On an underlying basis, turnover climbed from $1,027m to $1,148m, thanks to its Sports Medicine and Trauma & Extremities divisions, which benefitted from recent product launches and investment in the US sales force. The group reported success with its expansion plans for sports medicine, with the division seeing 11% revenue growth as it gained from the success of a number of recent product launches. Its other main area of expansion, wound-care markets, was as expected held back by US Negative Pressure Wound Therapy. The division reported a 3% decline in revenue, although this was still an improvement on the second quarter. The Advanced Surgical Devices division posted a 4% increase in revenue to $816m, thanks to growth across its Arthroscopic Enabling Technologies, Hip and Knee Implants and its overall performance in the US and Emerging & International Markets. The latter continued to deliver strong growth, with revenue up 20% in the quarter, including an improving contribution from its distributor acquisitions in Brazil. Group trading profit climbed from $222m to $246m, marking a gain of 3%, although on a reported basis it rose 10%. The trading profit margin was 21.4%, compared to 21.6% in the same period a year earlier. Chief executive officer Olivier Bohuon said: "We are delivering on our strategy to rebalance Smith & Nephew by strengthening our higher growth platforms, which currently represent more than half the business, up from just 35% three years ago. "Sports Medicine Joint Repair and Advanced Wound Bioactives both produced double-digit growth in the quarter, and the emerging markets business increased revenue by 20%. We are pleased with our momentum, enhanced by group optimisation, tax improvement and the acquisition of ArthroCare. Adjusted earnings per share grew 14% in the quarter. "The quarter positively reflects our strategy to rebalance towards higher growth markets, and we have many actions underway to further build upon these achievements." For the nine-month period, reported revenues were $3,368m, up 2% on an underlying basis year-on-year. Trading profit was $730m, against $695m a year earlier, although the trading profit margin slipped from 21.9% to 21.7%.
So the CEO announces the clinical trial failure. On top of the FDA issues with NPWT. The wound management division will be taking a huge hit end of this year and best part of next year I expect.
very steady volumes for the last week , wish JnJ would get a move on :-))
Zak Mir offers his Major Market Round-up and Market Discussion of the FTSE 100 and says Smith & Nephew (SN.) Buy and Hold - See more at:
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
ADVFN Advertorial
Your Recent History
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210519 00:51:22